
    
      This is a multicenter, nonrandomized, open-label, single-agent clinical study conducted in
      China, and is designed to investigate the use of bendamustine in the treatment of Chinese
      patients with relapsed, rituximab-refractory indolent NHL. The study consists of a screening
      period of up to 4 weeks, a treatment period of approximately 24 weeks (up to eight 21-day
      cycles), and a long-term follow-up period for up to 2 years after the last dose of study
      drug. Patients are expected to participate in this study for approximately 2.5 years.
    
  